The CryoLife-O'Brien composite stentless porcine aortic xenograft valve in 118 patients.

The CryoLife-O'Brien stentless valve is a composite trileaflet porcine aortic valve. It is assembled from 3 non-coronary leaflets and has no foreign material support. It is therefore truly stentless. From December 1992 to January 1996, 118 patients with aortic valve replacement had a CryoLife-O'Brien stentless valve inserted at the Prince Charles Hospital, Brisbane. The mean age was 73 years (range 59-89) and 54% were men. Most patients had aortic stenosis secondary to a calcific degenerative valve. Follow-up is 100% with hematological and echocardiographic studies before discharge, at 6 months, and at 12-18 months. Five deaths (2 early and 3 late) have occurred and morbidity includes 3 strokes, 1 peripheral embolism, 3 perivalvular leaks, and 1 patient with late endocarditis. Valve performance has been good, with low transvalvular gradients and only a trace or no regurgitation in over 95% of patients after 18 months. No structural deterioration or hemolysis has occurred. Echocardiographic surveillance confirms a very effective central orifice. Short-term results show that the overall performance of the CryoLife-O'Brien stentless valve has been very satisfactory, with low mortality and morbidity in this elderly group of patients. The benefits include the absence of prosthetic material, wide leaflet coaptation, and a quick and easy insertion. Long-term anticoagulation is not necessary. It is particularly suitable for elderly patients with a symmetrical aortic root.

Choice of replacement valve in the elderly.

BACKGROUND AND AIMS OF THE STUDY: Little comparative information exists on the outcome of the valve replacement with bioprostheses or mechanical valves in the elderly. This study was carried out to make such a comparison. METHODS: Follow up data were examined from 219 patients aged > or = 65 years who underwent aortic and/or mitral valve replacement using bioprosthetic (n = 67) or mechanical valve (n = 152) between April 1979 and December 1993. The mean follow up periods were 6.3 +/- 2.8 years after bioprosthesis and 4.9 +/- 2.1 years after mechanical valve implantation. RESULTS: Although the actuarial rate of structural deterioration was higher in patients with bioprosthetic valves than in those with mechanical valves (58% versus 100% freedom at 10 years after surgery, p < 0.01), no such prosthesis-related difference was seen in the subgroup of patients aged > or = 70 (100% versus 100% at nine years, p = N.S.). The actuarial rate of major bleeding was higher after mechanical valve implantation than after bioprosthetic valve placement (90% versus 100% freedom at 10 years, p < 0.05); this lower rate with bioprosthetic valves was maintained in patients aged > or = 70 (78% versus 100% at nine years, p < 0.05). There were no significant differences in the incidences of thromboembolism and bacterial endocarditis between the two valve types. CONCLUSIONS: Structural degeneration of bioprosthetic devices was a major problem in patients aged 65-70 years, but it was essentially negligible in those aged > or = 70 years. Anticoagulant-related bleeding was a major problem with mechanical valves in both age groups. Therefore, for patients older than 70 years, valve replacement with a bioprosthesis appears to be the method of choice.

Normal echocardiographic characteristics of the Sorin Bicarbon bileaflet prosthetic heart valve in the mitral and aortic positions.

Doppler echocardiographic characteristics of normally functioning Sorin Bicarbon prostheses were prospectively assessed in 226 consecutive patients (135 male and 91 female patients, mean age 61 +/- 10 years) with 233 valves in the mitral (n = 67) and aortic (n = 166) positions whose function was considered normal by clinical and echocardiographic evaluation. Patterns of "normal" transprosthetic leakage were assessed with transthoracic echocardiography in all valves and with transesophageal echocardiography in six selected mitral valve prostheses. For the mitral valve prostheses, we found that peak and mean gradient, as well as pressure half-time, were not significantly different in either the 25 or the 31 mm valves (median values from 15 to 10 mm Hg, from 4 to 4 mm Hg, and from 70 to 83 ms; p = Not significant for all). On transthoracic study, 12 patients (17%) with a Sorin Bicarbon valve in the mitral position showed minimal transprosthetic leakage. On transesophageal study, all patients showed a transprosthetic leakage whose spatial distribution had a complex pattern: in planes orthogonal to the leaflet axis, two to four jets arising from the hinge points and converging toward the center of the valve plane could be visualized; in planes parallel to the leaflet axis, there were three jets, the two lateral ones diverging and the central one perpendicular to the valve plane. For the aortic valve prostheses, there was a significant decrease in transprosthetic gradients and an increase in effective orifice areas as prosthesis size increased. Peak and mean gradients decreased from a median value of 25 and 13 mm Hg in the 19 mm valves to 9 and 5 mm Hg in the 29 mm valves, respectively. Effective prosthetic valve area calculated with the continuity equation increased from a median value of 0.97 cm2 for the 19 mm size valves to 3.45 cm2 for the 29 mm size. With analysis of variance, effective prosthetic aortic valve area differentiated various valve sizes (F = 40.9, p < 0.0001) better than peak (F = 10.3, p < 0.0001) or mean (F = 8.04, p < 0.0001) gradients alone did. Furthermore, effective prosthetic aortic valve area correlated better than peak and mean gradients with prosthetic size (r = 0.76, r = -0.45, and r = -0.39, respectively). On transthoracic study, 109 patients (66%) showed minimal transprosthetic leakage. These normal values, obtained in a large number of patients with normofunctioning mitral and aortic Sorin Bicarbon valves, may help to identify Sorin Bicarbon prosthesis dysfunction.

The Biomed caged-ball cardiac valve prosthesis. A study of 120 implants.

The purpose of this study was to report our experience with 120 prosthetic valves implanted in 105 patients over an 8-year period. Their preoperative status was compared at an average follow-up period of 4 years (range 1 to 6 years) with the postoperative results. We conclude that the Mexican-made valves (Biomed) meet the highest international quality standards: they are well tolerated by the patients; their performance is excellent and no postoperative dysfunction of the valves was ever detected. The few complications observed were no different from those reported for foreign ball-caged valves. Finally, most of our patients showed a marked improvement postoperatively.

Synergistic inhibition of calcification of porcine aortic root with preincubation in FeCl3 and alpha-amino oleic acid in a rat subdermal model.

Postimplant calcific degeneration is a frequent cause of clinical failure of glutaraldehyde crosslinked porcine aortic valve bioprostheses. We demonstrated previously in rat subdermal and circulatory implants that alpha-amino oleic acid used as a bioprosthesis pretreatment was highly effective in mitigating aortic valve cusp but not aortic wall calcification. In this study we investigated the feasibility of synergistically applying two proven anticalcification agents (alpha-amino oleic acid and FeCl3) as pretreatments for mitigating both bioprosthetic cusp and aortic wall calcification. alpha-Amino oleic acid is hypothesized to prevent calcification by disrupting calcium phosphate formation kinetics, whereas suppression of alkaline phosphatase activity and ferric-phosphate complexation at a cellular membrane initiation sites may be important factors in ferric ion's inhibition of calcification. In vivo implant studies (21-day rat subdermal model) indicated that individually FeCl3 (0.01 or 0.1 M for 24 h) or alpha-amino oleic acid (saturated solution) treatments were equally effective in mitigating cuspal calcification (tissue calcium levels: 30.2 +/- 10.2, 29.8 +/- 2.7, and 31.6 +/- 7.8 micrograms/mg tissue, respectively). However, sequential application of first alpha-amino oleic acid and then FeCl3 synergistically reduced aortic wall calcification more effectively than either of the agents alone. The benefit of a synergistic application of two anticalcification treatments, alpha-amino oleic acid and FeCl3, was demonstrated. However, the synergistic effect was observed on aortic wall only at a higher FeCl3 concentration. (i.e., 0.1 M).

Wear patterns in the Sorin Bicarbon mechanical heart valve: a clinical explant study.

BACKGROUND AND AIMS OF THE STUDY: Mechanical heart valve prostheses are subject to wear due to impact and friction between the occluder(s) and valve housing. Reference data on the extent of wear in vivo is lacking. Therefore, the aim of this study was to describe the wear pattern in Sorin Bicarbon valves explanted from humans for comparison with the findings established in an earlier in vitro study. METHODS: We investigated eight valves explanted from seven patients, which had been functioning for more than six months and were returned to the Sorin Company for investigation. The protocol comprised: (i) initial visual inspection on receipt; (ii) stereomicroscopy after cleaning and disassembly; (iii) computed planimetry of the worn areas in the housing; (iv) pivot surface profilometry; and (v) scanning electron microscopy. RESULTS: All wear depths and exposed areas of titanium were less than that predicted from in vitro figures. No valves were explanted due to mechanical failure and none of the patients had reported peripheral embolic events which could be attributed to valve wear. The extent of wear was comparable with that of other valves. CONCLUSIONS: This descriptive study did not indicate any association between the Bicarbon valve wear characteristics and clinical complications. Clinical studies on valve performance are of paramount importance for elucidating this issue. The establishment of an independent body for studying explanted valves in collaboration with the manufacturers may promote the publication of findings which are of interest for the entire medical community.

Hemodynamic characterization of the CarboMedics mitral valve prosthesis.

BACKGROUND AND AIMS OF THE STUDY: The hemodynamic function of the CarboMedics bileaflet mitral valve prosthesis was evaluated by Doppler echocardiography and by heart catheterization. The clinical state of the invasively examined patients was evaluated before and after surgery. METHODS: Doppler echocardiography was performed in 54 patients at six months after surgery. Further, combined right and left heart catheterization was performed in 22 of these patients before surgery and at six months thereafter. RESULTS: The Doppler mean gradients were small (3.6 +/- 1.2 mmHg), and corresponded well with Doppler mean gradients in the subgroup examined with both methods (3.5 +/- 1.1 mmHg) and with the invasive gradients (3.4 +/- 1.9 mmHg); there was also no difference between the different valve sizes. Clinically, pressure recovery distal to the valve is probably so small that no systematic difference between the two techniques of measurement is present. Only physiological regurgitation was found, and no case of valve dysfunction. The patients improved from functional NYHA class 3.1 +/- 0.4 to 1.4 +/- 0.6, regardless of preoperative diagnosis, with most pronounced improvement in those with mitral stenosis. Pulmonary artery pressure was normalized. Pulmonary vascular resistance and cardiac index improved slightly. CONCLUSIONS: In conclusion, the valvular prostheses demonstrated excellent hemodynamic function. There was striking agreement between the small invasive and non-invasive gradients. Finally, the functional status of the patients improved considerably, most distinctly in those patients with prior mitral stenosis.

Hemodynamics of St. Jude Medical prostheses in the small aortic root: in vivo studies using dobutamine Doppler echocardiography.

BACKGROUND AND AIMS OF THE STUDY: The well known correlation between prosthetic valve orifice area and transvalvular pressure drop has raised concerns about the presence of significant residual gradients when only a small-sized prosthesis can be implanted, particularly in patients with a large body surface area. The aim of this study was to study the hemodynamic performance of small-size St. Jude Medical aortic prostheses using dobutamine echocardiography. METHODS: Fifteen patients (14 females, one male, of mean age 67 years) who had undergone aortic valve replacement with size 19 mm St. Jude Medical prostheses at a mean of 19 +/- 8 (SD) months previously were studied. Dobutamine infusion was started at a rate of 5 micrograms/kg/min and increased to 10 and subsequently to 20 micrograms/kg/min at 15-min intervals. Pulsed and continuous-wave Doppler studies were performed at rest and at the end of each stage. Effective orifice area (EOA) and mean gradient across each prosthesis were calculated, and cardiac output (CO) was determined by Doppler measurement of flow in the left ventricular outflow tract. RESULTS: Dobutamine-stress increased heart rate and cardiac output by 57% and 86% respectively (both p < 0.0005), and mean transvalvular gradient increased from 22.0 +/- 4.9 mmHg at rest to 41.9 +/- 9 mmHg at maximum stress (p < 0.0001). Regression modeling analyses demonstrated that maximum stress gradient was independent of all variables except resting gradient (p = 0.0068). Body surface areas had no effect on the changes in cardiac output, effective orifice area or transprosthetic gradient at maximum stress. CONCLUSIONS: These data demonstrate that the size 19 mm St. Jude Medical prosthesis exhibits favorable hemodynamic performance. Transvalvular gradients remained within a clinically acceptable range, both at rest and under stress conditions. Moreover, in the patient population studied, overall hemodynamic performance indicates that with St. Jude Medical aortic valves, patient-prosthesis mismatch is unlikely to be a problem of clinical importance.

Discrepancy of sizers for conventional and stentless aortic valve implants.

BACKGROUND AND AIM OF THE STUDY: As the hemodynamic performance of an artificial heart valve is closely related to the size of the valve implanted, exact sizing of the prosthesis is important in aortic valve replacement. In the past, discrepancies have been recognized between the actual and labeled diameters of sizers used for conventional aortic valves; this study aimed to examine the accuracy of sizers for both conventional and stentless valves. METHODS: Currently used sets of sizers were analyzed using a high-precision digital micrometer with a resolution of 0.01 mm. Sizers of aortic bileaflet mechanical valves (ATS, CarboMedics, St. Jude Medical Standard, St. Jude Medical HP), conventional aortic bioprostheses (Carpentier Edwards) and stentless aortic bioprostheses (Freestyle, TorontoSPV) were analyzed. The diameters were recorded when the sizer could not be moved laterally while still able to be rotated. RESULTS: Results are given as mean +/- standard deviation for 20 repeat measurements. All mechanical valve sizers were 0.77 +/- 0.03 to 1.01 +/- 0.02 mm larger than labeled, whereas all bioprosthetic valve sizers proved to be sized as labeled (0 +/- 0.01 mm). CONCLUSIONS: Exact sizing is important in stentless valve replacement. The use of accurate sizers is recommended with other types of replacement valves as well. Results of valve replacement procedures worldwide would be more comparable if sizers of identical size were available in all operating rooms. As long as discrepancies between different sizers still exist, surgeons must be made aware of the problem.

Importance of leaflet elongation in causing systolic anterior motion of the mitral valve.

BACKGROUND AND AIMS OF THE STUDY: There is growing evidence for mitral leaflet elongation in patients with hypertrophic cardiomyopathy. Such elongation could predispose to systolic anterior motion (SAM) of the mitral valve by increasing leaflet mobility and providing a geometry that promotes this condition. METHODS: To test this postulate, five porcine mitral valves were studied in a physiologic left heart pulsatile flow duplicator. They were elongated with patches sutured to the basal posterior leaflet (three sizes per valve) or anterior leaflet (basal, middle, or distal). Each geometry was studied with normal papillary muscle position and with anterior and inward displacement, as seen in hypertrophic cardiomyopathy, to shift the leaflets into the outflow stream. RESULTS: Four points became clear. 1) Leaflet elongation promoted the development of SAM in response to papillary muscle displacement by creating long overlapping residual leaflets capable of moving anteriorly. 2) Posterior leaflet elongation also promoted SAM by shifting leaflet coaptation anteriorly, with progressive increases in SAM. 3) Basal and mid-anterior leaflet elongation caused SAM with prolapse; distal anterior leaflet elongation created SAM with a mobile flap (leaflet elongation without papillary muscle displacement created prolapse). 4) Residual leaflet length correlated well with total leaflet length (r = 0.87-0.98 for each valve), and the degree of SAM in turn correlated well with residual leaflet length (r = 0.62-0.98 for individual valves). CONCLUSIONS: Mitral leaflet elongation, by increasing the residual leaflet length and leaflet mobility, can play an important role in promoting SAM in response to outflow forces, as demonstrated by prospectively altering leaflet length. These findings are consistent with recent observations that reducing leaflet redundancy and posterior leaflet height can reduce obstructive SAM following mitral valve repair in patients with mitral valve prolapse and help relieve obstruction in patients with hypertrophic cardiomyopathy and enlarged leaflets.

Aortic valve replacement in small aortic annulus with or without annular enlargement.

BACKGROUND AND AIMS OF THE STUDY: Surgical treatments for aortic valve disease in the presence of a small aortic annulus need appropriate indications for operative procedures and precise selection of valve prostheses. The objective of this study was to compare long term results after aortic annular enlargement with those after operation using a small valve prosthesis. MATERIALS AND METHODS: Since 1980, 45 patients with small aortic annulus underwent operation at our institution. There were six men and 39 women, and their ages ranged from 16 to 69 with a mean of 45.6 years. Of these patients, 28 underwent aortic annular enlargements (Nicks' procedure in 13, Manouguian's in 12 and apico-aortic bypass in three patients) and 17 patients received standard aortic valve replacement with a small valve prosthesis (19 mm Standard St. Jude Medical). Mean follow up was 8.6 years in the enlargement group and 4.9 years in the standard group. RESULTS: Early mortality was 3.6% (1/28) in the enlargement group and 5.9% (1/17) in the standard group (NS). The 10-year actuarial survival including all deaths was 85.7% in the enlargement group and 62.7% in the standard group (p < 0.10). The rate of freedom from reoperation at 10 years was 90.7% in the enlargement group and 93.8% in the standard group (NS). The 10-year freedom from all valve-related events was 81.0% in the enlargement group and 58.8% in the standard group (p < 0.05). CONCLUSIONS: The above results suggest that long term mortality and morbidity after aortic annular enlargement might be superior to those after standard AVR with a small valve prosthesis.

Concomitant procedures in the small versus standard aortic root.

BACKGROUND AND AIMS OF THE STUDY: Aortic valve replacement (AVR) in the small aortic root (SAR) has always been a severe challenge with an uncertain surgical outcome. The purpose of this study was to assess the surgical and clinical performance of 19 mm and 21 mm CarboMedics valves (CPHV) based on a review of valve-related morbidity and mortality over a period of six years. METHODS: A total of 361 patients undergoing aortic valve replacement (AVR) with the CPHV between January 1989 and August 1995 was subdivided and studied. (i) Group A patients (n = 137) received 19 mm or 21 mm prostheses; subgroup AI (n = 85) underwent isolated AVR and subgroup AII (n = 52) underwent AVR with associated cardiac procedures. (ii) Group B patients (n = 224) were given 23 mm or larger prostheses; subgroup BI (n = 147) underwent isolated AVR and subgroup BII (n = 77) underwent AVR with concomitant cardiac procedures. RESULTS: Hospital mortality was group A 7.3% versus group B 4.9%. Cumulative survival after six years was 83.7% in AI and 76.9% in AII versus 72.1% in BI and 77.4% in BII. There were no significant statistical differences between the subgroups concerning cardiac mortality. Thromboembolic events occurred with a linearized rate of 1.41%/pty in group A versus 1.03%/pty in group B, the incidence of anticoagulant-related major hemorrhage was 1.41%/pty in group A versus 1.20%/pty in group B and that of periprosthetic leakage 1.69%/pty in group A versus 1.89%/pty in group B. CONCLUSION: Our results demonstrate that this bileaflet prosthesis is highly efficient in patients with small aortic roots undergoing AVR with or without associated procedures.

Stentless bioprostheses for the small aortic root.

BACKGROUND AND AIMS OF THE STUDY: Despite a variety of different artificial heart valves no ideal prosthesis for the small aortic root is yet available. Conventional stented valves are hemodynamically disadvantageous because of higher transvalvular pressure gradients. Stentless bioprostheses were implanted in such patients to evaluate their performance as an alternative to homografts and to conventional mechanical prostheses. MATERIALS AND METHODS: We analyzed 57 patients with small aortic roots who underwent stentless aortic valve replacement (Toronto SPV) from March 1993 to November 1995. All but two patients had aortic stenosis. The mean age at operation was 70.9 (+/-8.2) years. The annular diameter was 18-23 mm (mean 21.4 +/- 1.1 mm) in all patients. Of the 57 patients, 17 received a 23 mm and 40 patients a 25 mm prosthesis. RESULTS: Using the oversizing technique, valve size was adjusted according to the sinotubular junction diameter, allowing a gain in prosthesis size of 2-4 mm to be achieved in all patients. On pre-discharge echocardiography maximum flow velocity was 2.3 +/- 0.4 m/s, maximum pressure gradient was 19.1 +/- 6.8 mmHg, and effective valve orifice area was 1.46 +/- 0.27 cm2. All patients were in NYHA class I or II at discharge. One patient was reoperated due to a folded annulus caused by too much oversizing. At six months follow up there was a significant reduction in pressure gradients and an increase in effective valve orifice areas in relation to a decrease in pre-existing left ventricular hypertrophy. CONCLUSIONS: Stentless bioprostheses show excellent hemodynamics due to their comparably large internal diameter and flexibility. Controlled oversizing is a safe technique without additional complications. As larger valve sizes can be implanted, aortic root enlargement is not necessary. The superior hemodynamic profile of stentless aortic valves is especially advantageous in patients with small aortic roots.

Small aortic root in the elderly: use of stentless bioprosthesis.

BACKGROUND AND AIMS OF THE STUDY: Aortic root enlargement in the elderly patient prolongs aortic valve replacement procedures and may be problematic if the root is calcified. Mechanical valves have superior hemodynamics compared to tissue valves in the smaller sizes but are often contraindicated in the older patient. MATERIALS AND METHODS: Between January 1993 and November 1995, we implanted 80 Freestyle (Medtronic, Irvine, CA) stentless porcine valves using the freehand subcoronary technique. Twenty-seven of the patients had small aortic roots with an average age of 76.3 years (69-84). Seven patients received size 19 valves and 20 patients had size 21 valves. RESULTS: The average echocardiographic gradient at hospital discharge was 17.9 mmHg (12.1-23.0) for size 19 valves and 15.3 mmHg (5.7-27.9) for size 21. At one year postoperative follow up the average gradient had decreased to 12.9 mmHg (9.3-17.5) for size 19 and 8.0 mmHg (2.2-19.3) for size 21 valves. Effective orifice areas increased from 1.09 cm2 at the time of discharge to 1.29 cm2 at one year follow up for size 19 valves, and from 1.30 cm2 to 1.56 cm2 for size 21. No patient had more than mild aortic insufficiency at most recent follow up. CONCLUSION: This stentless porcine prosthesis has excellent hemodynamics in the smaller valve sizes which improve at least during the first year following surgery. We feel that it is the valve of choice in older patients with small aortic roots.

Stentless aortic valve replacement with the biocor prosthesis: indications and outcome.

BACKGROUND AND AIMS OF THE STUDY: Due to improved hemodynamic properties stentless bioprostheses represent a new therapeutic option in the surgical treatment of aortic valve disease. MATERIALS AND METHODS: Between February 1993 and June 1995 22 patients with a small aortic root regarded as suboptimal for a stented bioprosthesis (diameter < or = 23 mm, mean 21.6 +/- 1.9 mm) underwent aortic valve replacement with a Biocor stentless prosthesis. Mean age was 63.9 +/- 15.4 years (17-85 years). Valve size ranged from 21 to 27 mm (mean 25 mm) and exceeded the root diameter by 4 mm. As compared to a control group of patients with root enlargement (n = 10) total bypass time and cross-clamp time in the stentless group were significantly shorter (83.3 +/- 12.7 and 60.9 +/- 9.2 min versus 95.8 +/- 27.1 and 69.5 +/- 16.5 min, p = 0.054 and p < 0.05), respectively. RESULTS: Three patients died postoperatively unrelated to the choice of valve. There were no late deaths. No thromboembolic or bleeding events were observed. Follow up data are available over a period of 1-25 months (mean 12.5 months, median 16 months). Echocardiographic evaluation revealed no aortic regurgitation; mean valve gradients were 9.9 +/- 4.1 mmHg (peak 19.2 +/- 6.0 mmHg). For specific root diameters these gradients were compared to established data for Hancock bioprostheses demonstrating significant differences in transvalvular gradients between the two valve designs for given root diameters. Unloading the left ventricle resulted in regression of left ventricular hypertrophy (decrease in wall thickness from 13.6 +/- 1.7 mm to 11.2 +/- 2.0 mm). Exercise capacity improved from NYHA III-IV preoperative to I-II postoperative. CONCLUSIONS: In patients with a small aortic root stentless valves represent a new option. Compared to root enlargement with standard bioprosthesis myocardial ischemia is shorter and implantation of larger valve sizes results in superior hemodynamics.

The influence of the design on the medium to long-term hemodynamic behavior of 19 mm pericardial aortic valve prostheses.

BACKGROUND AND AIMS OF THE STUDY: The hemodynamics of five designs of 19 mm pericardial aortic valve bioprosthesis were examined by Doppler echocardiography in 48 resting patients at medium or long term follow up. METHODS: The salient differences among the five designs are that valve leaflets are mounted inside the support frame in one (the Carpentier-Edwards valve, evaluated in five patients) and outside the frame in the other four (the Ionescu-Shiley (14 patients), Mitroflow (six patients), Bioflo (eight patients) and Labcor-Santiago (15 patients)); and that two models have either total (Bioflo) or partial (Labcor-Santiago) protective pericardial sheaths on the stent, while the other three do not. The hemodynamic parameters determined included transvalvular pressure drop, valve area, left ventricular outflow tract diameter, subvalvular/valvular velocity ratio and subvalvular/valvular velocity-time integral ratio. RESULTS: There were no significant differences among the various valves as regards left ventricular outflow tract diameter, subvalvular/valvular velocity ratio or subvalvular/valvular velocity-time integral ratio. Negative correlation between left ventricular outflow tract diameter and subvalvular velocity (r = -0.63, p < 0.001) confirmed the need to correct for prevalvular velocities when using the Bernoulli equation to calculate the pressure drop across small pericardial aortic valve bioprostheses. The Bioflo design caused significantly greater pressure drops (peak 49.6 +/- 11.3 mmHg, mean 28.1 +/- 6.1 mmHg) and provided smaller areas (0.80 +/- 0.16 cm2) than the Ionescu-Shiley (26.7 +/- 6.6 and 15.2 +/- 4.1 mmHg, 1.17 +/- 0.17 cm2) and Labcor-Santiago (24.8 +/- 5.9 and 15.1 +/- 3.7 mmHg, 1.24 +/- 0.12 cm2) valves. CONCLUSIONS: Of the currently available 19 mm bovine pericardium heart valve bioprostheses, the Mitroflow and Labcor-Santiago valves, in both of which the leaflets are mounted outside the stent, have better hemodynamics in the aortic position than the Carpentier-Edwards valve, which has internal leaflet mounting. Sheathing the stent totally in pericardium, as in the withdrawn Bioflo valve, gives rise to relatively poor hemodynamics.

Aortic valve replacement in elderly women with small aortic roots: comparing sorin pericardial and St. Jude Medical mechanical valves.

After implanting 19mm and 21mm Sorin pericardial aortic valves (AVR) in 35 women over the age of 60 years, it was our clinical impression that these patients had an unduly high incidence of residual valve stenosis. A retrospective comparison of our experience with this valve and the 19mm St. Jude mechanical AVR in a similar group of 26 patients, operated during the same period (October 1987 to July 1994), was carried out. In comparison to the 19mm St. Jude valve, the 19 mm Sorin Pericardial valve was associated with significant residual stenosis in elderly women despite similar body surface areas. This prosthesis/patient mismatch was not eliminated by the use of a 21 mm Sorin pericardial valve. Although the Sorin pericardial valves was associated with a reduced incidence of thromboembolism and anticoagulation related hemorrhage, it had a significantly increased risk of permanent valve related morbidity and mortality. As a result if this experience we have discontinued our use of the Sorin pericardial valve.